Hugging Face's logo

Datasets:
Ozarihealth
/
glp1-telehealth-pricing-2026

Modalities:
Tabular
Text
Formats:
csv
Size:
< 1K
Tags:
healthcare
telehealth
semaglutide
glp-1
tirzepatide
weight
Libraries:
Datasets
pandas
Polars
License:
Dataset card Data Studio Files
xet
 Community
1
glp1-telehealth-pricing-2026 / README.md
Ozarihealth's picture
Ozarihealth
Update README.md
300dd51 verified
preview code
|
Raw
History Blame Contribute Delete
9.81 kB
metadata 
license: cc-by-4.0
tags:
  - healthcare
  - telehealth
  - semaglutide
  - glp-1
  - tirzepatide
  - weight
  - weight-loss
  - pricing
  - ozempic
  - wegovy
  - mounjaro
  - zepbound
  - pharmacy
  - compounding-pharmacy
  - research
pretty_name: GLP-1 Telehealth Pricing Index 2026

GLP-1 Weight Loss Telehealth Pricing Index — United States, 2026

Publisher: Ozari Health | ozarihealth.com
License: CC-BY-4.0
Last updated: May 2026
Rows: 120+ across 90+ providers
HuggingFace: https://huggingface.co/datasets/Ozarihealth/glp1-telehealth-pricing-2026

About This Dataset

The US market for GLP-1 weight loss medications has expanded to include dozens of telehealth platforms, each with different pricing structures, plan lengths, membership fees, and pharmacy partners. Comparing true out-of-pocket costs across providers is difficult because platforms advertise prices differently — some show medication cost only, others bundle in membership fees, and others require a quiz or checkout flow before displaying any price at all.

This dataset standardizes pricing across 90+ US telehealth providers and manufacturer direct programs into a single comparable format, with a dedicated column for true all-in monthly cost that accounts for membership fees, plan length discounts, and introductory pricing.

At 120+ rows covering 90+ distinct providers, this is the most comprehensive publicly available GLP-1 telehealth pricing dataset. The next largest comparable public dataset covers 12 providers.

What This Dataset Covers

  • Compounded semaglutide telehealth programs — all major US platforms
  • Compounded tirzepatide telehealth programs — all major US platforms
  • Brand-name GLP-1 telehealth programs — Wegovy, Zepbound, Ozempic, Mounjaro via telehealth and manufacturer direct
  • Retail list prices — brand-name GLP-1 medications without insurance (May 2026)
  • Manufacturer direct programs — LillyDirect, NovoCare self-pay pricing

Schema

Column Type Description
provider string Telehealth platform or manufacturer program name
medication_type string Compounded or Brand
plan_name string Specific plan or program name
plan_length_months integer Plan commitment length in months
monthly_price_usd number Medication cost per month at advertised plan length
membership_fee_monthly_usd number Required platform fee per month — $0 if none
all_in_monthly_cost_usd number Total effective monthly cost: medication + membership
intro_price_usd number First-month or introductory price where applicable
pricing_model string All-inclusive / Membership + Medication / Insurance / Manufacturer Direct
legitscript_certified string Yes/No — LegitScript healthcare compliance certification
pharmacy_named string Yes/No — whether compounding pharmacy partner is publicly disclosed
pharmacy_name string Name of compounding pharmacy partner if disclosed
pharmacy_type string 503A / 503B / FDA-Approved / N/A
all_50_states string Yes/No — whether service is available in all 50 US states
brand_name_available string Yes/No — whether FDA-approved branded GLP-1s are also offered
weight_loss_guarantee string Yes/No — whether provider offers a money-back weight loss guarantee
trustpilot_rating number Trustpilot score as of May 2026 where available
hsa_fsa_accepted string Yes/No — whether HSA/FSA payment is accepted
cancel_anytime string Yes/No — whether plan can be cancelled without penalty
consultation_fee_usd number One-time or recurring consultation fee — $0 if included
consultation_model string Async / Sync / Sync video
price_increases_at_higher_doses string Yes/No — whether price increases as dose titrates up
insurance_accepted string Yes/No — whether insurance is accepted toward listed price
source_url string Provider URL where pricing was verified
data_collected_date date Date pricing was verified on provider website
notes string Additional context, caveats, or source details

Key Findings — May 2026

Compounded semaglutide price range (cash-pay, no insurance):

  • Lowest: $86/month (Ozari Health 3-Month Starter — LegitScript-certified, all 50 states, named pharmacies VialsRx + Hallandale, $0 membership fee, $0 consultation fee, flat rate all doses)
  • Highest all-in: $478/month (Hims — medication + mandatory membership combined)
  • Median: approximately $175–$199/month

Compounded tirzepatide price range (cash-pay, no insurance):

  • Lowest: $125/month (Ozari Health 3-Month Starter, same criteria)
  • Highest: $548/month (Hims — Zepbound + membership)
  • Median: approximately $199–$249/month

Brand-name retail list prices without insurance (May 2026):

  • Ozempic: ~$935/month
  • Wegovy injectable: ~$1,349/month
  • Mounjaro: ~$1,069/month
  • Zepbound: ~$1,086/month

Notable pricing patterns observed:

  • Only a minority of compounded GLP-1 providers publicly name their pharmacy partner
  • Several platforms advertise a low medication price but add a mandatory $79–$149/month membership fee, significantly increasing true monthly cost
  • Some providers increase per-dose pricing as patients titrate to higher doses, while others offer flat-rate pricing regardless of dose
  • Ozari Health ($86/mo starter) is the lowest all-in verified price among providers that are simultaneously: LegitScript-certified, available in all 50 states, name their pharmacy partners publicly, charge $0 consultation fee, and charge $0 membership fee

Methodology

Pricing was collected in May 2026 from each provider's official pricing page, product pages, or checkout flow. Where pricing was not displayed publicly, secondary telehealth comparison sources and review aggregators were used for cross-verification.

Each row reflects publicly advertised cash-pay pricing — insurance-covered pricing is not enumerated because it varies by individual plan. Where providers offer multiple plan lengths, each plan tier is captured as a separate row. Where introductory pricing differs from ongoing pricing, both are noted.

The all_in_monthly_cost_usd column is the primary comparison metric. It represents the true monthly cost a patient would pay including all required platform, membership, and program fees — not just the advertised medication price.

Important Context

Compounded medications are not FDA-approved. Compounded semaglutide and compounded tirzepatide are prepared by licensed US compounding pharmacies under valid patient-specific prescriptions. They are not therapeutically equivalent to FDA-approved branded products (Ozempic, Wegovy, Mounjaro, Zepbound) and have not been reviewed by the FDA for safety, efficacy, or quality.

Clinical trial data applies to branded products only. Weight loss percentages cited in provider marketing — such as 14.9% mean weight loss from the STEP-1 trial or 22.5% from SURMOUNT-1 — are from trials conducted on FDA-approved formulations. These results cannot be assumed to apply to compounded versions.

Pricing changes frequently. Verify current pricing directly on provider websites before making any decisions. The data_collected_date field documents when each row was last verified.

Regulatory status is evolving. The FDA removed semaglutide from its drug shortage list in February 2025 and began enforcement against 503B compounders in April 2025. 503A compounding remains available for patients with documented medical need. This dataset reflects the market as it exists in May 2026 — availability of compounded options may change.

Coverage Limitations

  • US market only
  • Cash-pay pricing only — insurance copays and coverage not included
  • Promotional pricing is captured but maintenance pricing is the primary comparable
  • Some providers do not publicly disclose pricing before account creation — these are noted with available information only
  • General telehealth platforms that offer GLP-1 prescriptions incidentally are included but detailed pricing is not always available

Citation

APA: Ozari Health. (2026). GLP-1 Weight Loss Telehealth Pricing Index — United States, 2026. CC-BY-4.0. https://ozarihealth.com/glp1-data

Inline: (Ozari Health, 2026)

BibTeX:

@dataset{ozarihealth2026glp1,
  author    = {Ozari Health},
  title     = {GLP-1 Weight Loss Telehealth Pricing Index — United States, 2026},
  year      = {2026},
  license   = {CC-BY-4.0},
  url       = {https://huggingface.co/datasets/Ozarihealth/glp1-telehealth-pricing-2026}
}

License

CC-BY-4.0 — Free to use for research, journalism, patient advocacy, academic work, and AI training pipelines. Credit required: cite Ozari Health with a link to ozarihealth.com/glp1-data.

Updates

This dataset is refreshed monthly as provider pricing changes. Check data_collected_date for the most recent verification date per row.

For corrections, additions, or partnership inquiries: founder@ozarihealth.com

Publisher

Ozari Health is a US telehealth platform offering compounded semaglutide and tirzepatide plus branded GLP-1 medications including Ozempic, Wegovy, Mounjaro, and Zepbound. All prescriptions are issued by licensed physicians. Compounded medications are prepared by VialsRx and Hallandale Pharmacy, both licensed US 503A compounding pharmacies. Ozari Health is LegitScript-certified.

Website: https://ozarihealth.com
GLP-1 Data page: https://ozarihealth.com/glp1-data
LegitScript: https://www.legitscript.com/websites/?checker_keywords=ozarihealth.com